European Medicines Agency (EMA) | What's new 日本語 フォロー Orphan Drug Designation: Human bispecific monoclonal antibody targeting ALK1 and BMPRII for the treatment of hereditary hemorrhagic telangiectasia, 18/07/2025 Positive Orphan designation: human bispecific monoclonal antibody targeting ALK1 and BMPRII Treatment of hereditary haemorrhagic telangiectasia, 18/07/2025 Positive ema.europa.eu
